Storia in 3 fonti

Wockhardt shares pause massive 36% rally in 5 sessions; slip 7%. What’s behind the selloff?

Wockhardt shares dropped after a recent surge, as investors took profits. This followed the US FDA approval of ZAYNICH, an antibiotic for urinary tract infections. The company also reported a strong turnaround in its March quarter results. Revenue and profit saw significant year-on-year growth. Biotech operations were a key driver of this improved performance.

Raccontata da

economictimes.indiatimes.com

thehindubusinessline.com

timesofindia.indiatimes.com

Confronto fonti

3 prospettive sulla stessa storia

AI · summaries

thehindubusinessline.com3 mesi fa

Wockhardt shares tumble 9% amid profit booking after sharp rally on Zaynich approval

Wockhardt gained FDA approval for Zaynich (novel antibiotic for UTIs); stock surged 36.77% then fell 9% on profit-taking. Independent global distribution by Wockhardt marks India's first self-developed breakthrough drug without pharma partnerships.

Leggi questa versione → originale

Timeline cronologica

lunedì 1 giugno 2026·economictimes.indiatimes.com
FDA approval puts Wockhardt’s Zaynich in $9 billion antibiotics market
Wockhardts newly approved antibiotic Zaynich has the potential to transform the treatment of drug-resistant infections, according to Mahesh Patel, the scientist behind the drug.…
lunedì 1 giugno 2026·economictimes.indiatimes.com
Wockhardt shares in focus after FDA approval for antibiotic targeting drug-resistant infections. Check details

Wockhardt will be in focus after the US FDA approved ZAYNICH, a novel intravenous antibiotic combining cefepime and zidebactam for complicated urinary tract infections. The drug…

Wockhardt shares pause massive 36% rally in 5 sessions; slip 7%. What’s behind the selloff?

Confronto fonti

Wockhardt shares tumble 9% amid profit booking after sharp rally on Zaynich approval

Timeline cronologica

FDA approval puts Wockhardt’s Zaynich in $9 billion antibiotics market

Wockhardt shares in focus after FDA approval for antibiotic targeting drug-resistant infections. Check details

If you have the patience, you can achieve innovation milestones, says Wockhardt chairman Habil Khorakiwala

'USFDA nod for Zaynich a major boost'

Wockhardt marks research milestone with USFDA approval for novel antibiotic Zaynich

If you have the patience, you can achieve innovation milestones, says Wockhardt chairman Habil Khorakiwala

'USFDA nod for Zaynich a major boost'

Zaynich's blockbuster potential lifts Wockhardt's long-term outlook

Wockhardt shares tumble 9% amid profit booking after sharp rally on Zaynich approval

Wockhardt shares pause massive 36% rally in 5 sessions; slip 7%. What’s behind the selloff?